Spruce Biosciences Inc. Common Stock (SPRB)
Stock · NASDAQ · Health Care
$39.73as of 10/16/2026
Price chart
Active signals
SPRB Signal Track Record
How signals performed across all stocks →What SPRB's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 21 | -6.7% | 29% | July 15, 2026 |
| Bollinger Band Breakout | 18 | -2.9% | 33% | August 13, 2026 |
| Volume Spike | 6 | -18.5% | 0% | August 27, 2026 |
| Any 20-session window (baseline) | -3.8% | 42% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SPRB
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder char…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 22
- Website
- sprucebio.com/
Fundamentals
- 1-day range
- $39.21$41.53
- Market cap
- $127.76M
- P/E (trailing)
- —
- P/E (forward)
- 7.97
- EPS (trailing)
- $-38.31
- Dividend yield
- —
- Beta
- 3.63
- Avg. volume
- 77.9K
How Spruce Biosciences Inc. Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Apr 15, 2025 · via SEC EDGAR / Finnhub
Forecasts
9 analyst ratings
Spruce Biosciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- SPRBSpruce Biosciences Inc. Common Stock$39.65▼ 4.39%Market cap $127.76MP/E —$38.06$179.95
- IFRXInflaRx N.V. Common Stock$1.32▼ 8.33%Market cap $124.34MP/E —$0.7984$2.95
- TLSATiziana Life Sciences Ltd. Common Shares$1.05▲ 0.00%Market cap $123.99MP/E —$0.7615$2.2
- EQEquillium Inc. Common Stock$1.19▼ 9.85%Market cap $134.04MP/E —$0.76$3.54
- GNLXGenelux Corporation Common Stock$2.42▼ 2.42%Market cap $121.07MP/E —$2.29$8.54
- HURATuHURA Biosciences Inc. Common Stock$1.76▼ 3.83%Market cap $134.69MP/E —$0.41$3.43
- PMNProMIS Neurosciences Inc. Common Shares (ON)$8.15▼ 6.32%Market cap $119.54MP/E —$6.27$27.4
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SPRB Spruce Biosciences Inc. Common Stock | $127.76M | — | $39.65 | ▼ 4.39% | $38.06$179.95 |
| IFRX InflaRx N.V. Common Stock | $124.34M | — | $1.32 | ▼ 8.33% | $0.7984$2.95 |
| TLSA Tiziana Life Sciences Ltd. Common Shares | $123.99M | — | $1.05 | ▲ 0.00% | $0.7615$2.2 |
| EQ Equillium Inc. Common Stock | $134.04M | — | $1.19 | ▼ 9.85% | $0.76$3.54 |
| GNLX Genelux Corporation Common Stock | $121.07M | — | $2.42 | ▼ 2.42% | $2.29$8.54 |
| HURA TuHURA Biosciences Inc. Common Stock | $134.69M | — | $1.76 | ▼ 3.83% | $0.41$3.43 |
| PMN ProMIS Neurosciences Inc. Common Shares (ON) | $119.54M | — | $8.15 | ▼ 6.32% | $6.27$27.4 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual MeetingYahoo · 10/8/2026
- Citizens Reiterates Market Outperform on Spruce Biosciences, Maintains $144 Price TargetBenzinga · 9/24/2026
- Lake Street Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $149Benzinga · 9/17/2026
Insider Activity
Insider Actions →- Quartel Adrian W · July 27, 2026 · Grant13.0K
- Javier B. Szwarcberg · June 30, 2026 · Grant266 @ $4.53
- Walbert Keli · May 21, 2026 · Grant1.7K
- Barretto-Ko Percival · May 21, 2026 · Grant1.7K
- SIMPSON CAMILLA V · May 21, 2026 · Grant1.7K
- GREY MICHAEL G · May 21, 2026 · Grant1.7K
- Daniel K. Spiegelman · May 21, 2026 · Grant1.7K
Institutional Ownership
March 31, 2026
- Total shares held
- 699.4K
- Total value held
- $45.71M
- Institutional holders
- 30
- Unknown121.4K
- Unknown111.9K
- Unknown70.0K
- Unknown58.6K
- Unknown51.7K
- Unknown48.8K
- Unknown42.1K
- Unknown40.0K
- Unknown38.6K
- Unknown26.8K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Citizens Maintains $144 Target for Spruce Biosciences
Citizens Capital Markets has reaffirmed a market‑outperform rating for Spruce Biosciences and kept its $144 price target. The target sits well above the current trading level and within the company’s 52‑week range, suggesting upside potential. Analysts average a target of $148, with a wide range from $104 to $230. The stock’s RSI of 37.6 and a support level at $48.43 indicate it is not in overbought territory.
Citizens Maintains $144 Target for Spruce Biosciences. Citizens Capital Markets has reaffirmed a market‑outperform rating for Spruce Biosciences and kept its $144 price target. The target sits well above the current trading level and within the company’s 52‑week range, suggesting upside potential. Analysts average a target of $148, with a wide range from $104 to $230. The stock’s RSI of 37.6 and a support level at $48.43 indicate it is not in overbought territory.